Generative AI Molecule Discovery & Repurposing Market Forecasts to 2034 – Global Analysis By Product (AI-Driven Drug Design Platforms, Molecule Generation Software, Drug Repurposing Engines, Virtual Screening Platforms, Other Products), By Component, By Technology, By Application, By End User and By Geography
According to Stratistics MRC, the Global Generative AI Molecule Discovery & Repurposing Market is accounted for $4.6 billion in 2026 and is expected to reach $49.5 billion by 2034 growing at a CAGR of 30% during the forecast period. Generative AI Molecule Discovery & Repurposing involves the use of artificial intelligence models to design new chemical compounds or identify new therapeutic uses for existing drugs. These AI systems analyze large biological and chemical datasets to generate potential drug candidates with optimized properties. They can simulate molecular interactions, predict efficacy, and accelerate early-stage drug discovery. By reducing research timelines and development costs, generative AI helps pharmaceutical companies identify promising treatments more efficiently while expanding opportunities for repurposing approved drugs for new diseases.
Market Dynamics:
Driver:
Accelerating drug discovery with AI
AI algorithms enable rapid identification of novel molecules and predictive modeling of therapeutic outcomes. This significantly reduces the time and cost associated with traditional drug development. Pharmaceutical and biotech firms are increasingly adopting AI platforms to enhance R&D efficiency. Partnerships between AI developers and research institutions are further strengthening adoption. This technological momentum continues to propel global market growth.
Restraint:
High computational infrastructure costs
Generative AI platforms require advanced hardware, cloud computing resources, and specialized expertise. Smaller firms and startups often struggle to afford these investments. Ongoing maintenance and data management add to operational expenses. Limited access to affordable infrastructure slows adoption in emerging regions. These financial barriers continue to restrict broader market penetration.
Opportunity:
Repurposing existing drugs for new indications
Generative AI can analyze molecular structures and predict alternative applications for approved drugs. This approach reduces development timelines and regulatory hurdles compared to novel drug creation. Pharmaceutical firms are leveraging AI-driven repurposing to expand product pipelines. Collaborations with healthcare providers and research institutions are enhancing credibility. This opportunity is expected to drive innovation and cost efficiency in the sector.
Threat:
Regulatory uncertainty for AI-designed drugs
Approval processes for AI-designed molecules remain unclear in many jurisdictions. Lack of standardized frameworks creates challenges for commercialization. Regulatory delays discourage investment in AI-driven drug discovery. Concerns about transparency and explainability of AI models further complicate compliance. This uncertainty continues to challenge the scalability of generative AI in pharmaceuticals.
Covid-19 Impact:
The Covid-19 pandemic accelerated interest in AI-driven drug discovery. Urgent demand for treatments and vaccines highlighted the need for faster R&D processes. Generative AI platforms were leveraged to identify potential molecules and repurpose existing drugs. Increased funding for biotech and AI startups boosted innovation. Remote collaboration tools supported global research efforts during lockdowns. Overall, Covid-19 reinforced the relevance of AI in building resilient drug discovery pipelines.
The software platforms segment is expected to be the largest during the forecast period
The software platforms segment is expected to account for the largest market share during the forecast period as AI-driven tools form the backbone of molecule discovery. Pharmaceutical and biotech firms rely on advanced platforms for predictive modeling and molecular design. Continuous innovation in algorithms enhances accuracy and efficiency. Cloud-based solutions are expanding accessibility across regions. Rising demand for integrated platforms further strengthens this segment’s dominance.
The biotechnology companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the biotechnology companies segment is predicted to witness the highest growth rate due to their agility in adopting AI-driven solutions. Biotech firms are increasingly leveraging generative AI to accelerate drug pipelines and repurpose molecules. Rising venture capital investments are fueling adoption among startups. Collaborations with AI developers and pharmaceutical firms are driving innovation. Growing demand for precision medicine is further boosting this segment.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and strong R&D investments. The U.S. leads in AI adoption for drug discovery, with established pharmaceutical and biotech firms driving innovation. Regulatory frameworks and funding initiatives further support commercialization. Strong venture capital presence accelerates startup growth. Academic collaborations enhance credibility and adoption.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid advancements in healthcare and biotechnology. Countries such as China, India, and Japan are witnessing increased adoption of AI-driven drug discovery platforms. Government-backed initiatives and funding programs are boosting innovation. Local startups are entering the market with cost-effective solutions, expanding accessibility. Expansion of digital infrastructure and cloud computing is further supporting growth.
Key players in the market
Some of the key players in Generative AI Molecule Discovery & Repurposing Market include Insilico Medicine, Exscientia plc, BenevolentAI, Recursion Pharmaceuticals, Inc., Schr?dinger, Inc., Atomwise, Inc., XtalPi Inc., Generate Biomedicines, Deep Genomics Inc., Relay Therapeutics, Inc., IBM Corporation, Alphabet Inc., Microsoft Corporation, NVIDIA Corporation and Absci Corporation.
Key Developments:
In January 2026, Insilico launched the Science MMAI Gym, a new domain-specific training environment designed to transform general-purpose Large Language Models (LLMs) into high-performance engines for pharmaceutical-grade drug discovery tasks.
In February 2024, Exscientia signed a collaboration worth up to $674 million with the German Merck to discover novel small-molecule candidates across oncology, neurology, and immunology. The deal included a $20 million upfront payment for three initial research programs.
Products Covered:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Accelerating drug discovery with AI
AI algorithms enable rapid identification of novel molecules and predictive modeling of therapeutic outcomes. This significantly reduces the time and cost associated with traditional drug development. Pharmaceutical and biotech firms are increasingly adopting AI platforms to enhance R&D efficiency. Partnerships between AI developers and research institutions are further strengthening adoption. This technological momentum continues to propel global market growth.
Restraint:
High computational infrastructure costs
Generative AI platforms require advanced hardware, cloud computing resources, and specialized expertise. Smaller firms and startups often struggle to afford these investments. Ongoing maintenance and data management add to operational expenses. Limited access to affordable infrastructure slows adoption in emerging regions. These financial barriers continue to restrict broader market penetration.
Opportunity:
Repurposing existing drugs for new indications
Generative AI can analyze molecular structures and predict alternative applications for approved drugs. This approach reduces development timelines and regulatory hurdles compared to novel drug creation. Pharmaceutical firms are leveraging AI-driven repurposing to expand product pipelines. Collaborations with healthcare providers and research institutions are enhancing credibility. This opportunity is expected to drive innovation and cost efficiency in the sector.
Threat:
Regulatory uncertainty for AI-designed drugs
Approval processes for AI-designed molecules remain unclear in many jurisdictions. Lack of standardized frameworks creates challenges for commercialization. Regulatory delays discourage investment in AI-driven drug discovery. Concerns about transparency and explainability of AI models further complicate compliance. This uncertainty continues to challenge the scalability of generative AI in pharmaceuticals.
Covid-19 Impact:
The Covid-19 pandemic accelerated interest in AI-driven drug discovery. Urgent demand for treatments and vaccines highlighted the need for faster R&D processes. Generative AI platforms were leveraged to identify potential molecules and repurpose existing drugs. Increased funding for biotech and AI startups boosted innovation. Remote collaboration tools supported global research efforts during lockdowns. Overall, Covid-19 reinforced the relevance of AI in building resilient drug discovery pipelines.
The software platforms segment is expected to be the largest during the forecast period
The software platforms segment is expected to account for the largest market share during the forecast period as AI-driven tools form the backbone of molecule discovery. Pharmaceutical and biotech firms rely on advanced platforms for predictive modeling and molecular design. Continuous innovation in algorithms enhances accuracy and efficiency. Cloud-based solutions are expanding accessibility across regions. Rising demand for integrated platforms further strengthens this segment’s dominance.
The biotechnology companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the biotechnology companies segment is predicted to witness the highest growth rate due to their agility in adopting AI-driven solutions. Biotech firms are increasingly leveraging generative AI to accelerate drug pipelines and repurpose molecules. Rising venture capital investments are fueling adoption among startups. Collaborations with AI developers and pharmaceutical firms are driving innovation. Growing demand for precision medicine is further boosting this segment.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and strong R&D investments. The U.S. leads in AI adoption for drug discovery, with established pharmaceutical and biotech firms driving innovation. Regulatory frameworks and funding initiatives further support commercialization. Strong venture capital presence accelerates startup growth. Academic collaborations enhance credibility and adoption.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid advancements in healthcare and biotechnology. Countries such as China, India, and Japan are witnessing increased adoption of AI-driven drug discovery platforms. Government-backed initiatives and funding programs are boosting innovation. Local startups are entering the market with cost-effective solutions, expanding accessibility. Expansion of digital infrastructure and cloud computing is further supporting growth.
Key players in the market
Some of the key players in Generative AI Molecule Discovery & Repurposing Market include Insilico Medicine, Exscientia plc, BenevolentAI, Recursion Pharmaceuticals, Inc., Schr?dinger, Inc., Atomwise, Inc., XtalPi Inc., Generate Biomedicines, Deep Genomics Inc., Relay Therapeutics, Inc., IBM Corporation, Alphabet Inc., Microsoft Corporation, NVIDIA Corporation and Absci Corporation.
Key Developments:
In January 2026, Insilico launched the Science MMAI Gym, a new domain-specific training environment designed to transform general-purpose Large Language Models (LLMs) into high-performance engines for pharmaceutical-grade drug discovery tasks.
In February 2024, Exscientia signed a collaboration worth up to $674 million with the German Merck to discover novel small-molecule candidates across oncology, neurology, and immunology. The deal included a $20 million upfront payment for three initial research programs.
Products Covered:
- AI-Driven Drug Design Platforms
- Molecule Generation Software
- Drug Repurposing Engines
- Virtual Screening Platforms
- Other Products
- Software Platforms
- AI Algorithms & Models
- Data Libraries
- Cloud Infrastructure
- Computational Chemistry Tools
- Other Components
- Deep Learning
- Transformer Models
- Graph Neural Networks
- Reinforcement Learning
- Other Technologies
- Oncology Drug Discovery
- Rare Disease Drug Development
- Infectious Disease Research
- CNS Drug Discovery
- Immunology & Inflammation
- Other Applications
- Pharmaceutical Companies
- Biotechnology Companies
- CROs
- Academic Research Institutes
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY PRODUCT
5.1 AI-Driven Drug Design Platforms
5.2 Molecule Generation Software
5.3 Drug Repurposing Engines
5.4 Virtual Screening Platforms
5.5 Other Products
6 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY COMPONENT
6.1 Software Platforms
6.2 AI Algorithms & Models
6.3 Data Libraries
6.4 Cloud Infrastructure
6.5 Computational Chemistry Tools
6.6 Other Components
7 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY TECHNOLOGY
7.1 Deep Learning
7.2 Transformer Models
7.3 Graph Neural Networks
7.4 Reinforcement Learning
7.5 Other Technologies
8 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY APPLICATION
8.1 Oncology Drug Discovery
8.2 Rare Disease Drug Development
8.3 Infectious Disease Research
8.4 CNS Drug Discovery
8.5 Immunology & Inflammation
8.6 Other Applications
9 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY END USER
9.1 Pharmaceutical Companies
9.2 Biotechnology Companies
9.3 CROs
9.4 Academic Research Institutes
9.5 Other End Users
10 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY GEOGRAPHY
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kingdom
10.2.2 Germany
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Belgium
10.2.8 Sweden
10.2.9 Switzerland
10.2.10 Poland
10.2.11 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Thailand
10.3.8 Malaysia
10.3.9 Singapore
10.3.10 Vietnam
10.3.11 Rest of Asia Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Colombia
10.4.4 Chile
10.4.5 Peru
10.4.6 Rest of South America
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.1.1 Saudi Arabia
10.5.1.2 United Arab Emirates
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 Rest of Middle East
10.5.2 Africa
10.5.2.1 South Africa
10.5.2.2 Egypt
10.5.2.3 Morocco
10.5.2.4 Rest of Africa
11 STRATEGIC MARKET INTELLIGENCE
11.1 Industry Value Network and Supply Chain Assessment
11.2 White-Space and Opportunity Mapping
11.3 Product Evolution and Market Life Cycle Analysis
11.4 Channel, Distributor, and Go-to-Market Assessment
12 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
12.1 Mergers and Acquisitions
12.2 Partnerships, Alliances, and Joint Ventures
12.3 New Product Launches and Certifications
12.4 Capacity Expansion and Investments
12.5 Other Strategic Initiatives
13 COMPANY PROFILES
13.1 Insilico Medicine
13.2 Exscientia plc
13.3 BenevolentAI
13.4 Recursion Pharmaceuticals, Inc.
13.5 Schr?dinger, Inc.
13.6 Atomwise, Inc.
13.7 XtalPi Inc.
13.8 Generate Biomedicines
13.9 Deep Genomics Inc.
13.10 Relay Therapeutics, Inc.
13.11 IBM Corporation
13.12 Alphabet Inc.
13.13 Microsoft Corporation
13.14 NVIDIA Corporation
13.15 Absci Corporation
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY PRODUCT
5.1 AI-Driven Drug Design Platforms
5.2 Molecule Generation Software
5.3 Drug Repurposing Engines
5.4 Virtual Screening Platforms
5.5 Other Products
6 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY COMPONENT
6.1 Software Platforms
6.2 AI Algorithms & Models
6.3 Data Libraries
6.4 Cloud Infrastructure
6.5 Computational Chemistry Tools
6.6 Other Components
7 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY TECHNOLOGY
7.1 Deep Learning
7.2 Transformer Models
7.3 Graph Neural Networks
7.4 Reinforcement Learning
7.5 Other Technologies
8 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY APPLICATION
8.1 Oncology Drug Discovery
8.2 Rare Disease Drug Development
8.3 Infectious Disease Research
8.4 CNS Drug Discovery
8.5 Immunology & Inflammation
8.6 Other Applications
9 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY END USER
9.1 Pharmaceutical Companies
9.2 Biotechnology Companies
9.3 CROs
9.4 Academic Research Institutes
9.5 Other End Users
10 GLOBAL GENERATIVE AI MOLECULE DISCOVERY & REPURPOSING MARKET, BY GEOGRAPHY
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kingdom
10.2.2 Germany
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Netherlands
10.2.7 Belgium
10.2.8 Sweden
10.2.9 Switzerland
10.2.10 Poland
10.2.11 Rest of Europe
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Thailand
10.3.8 Malaysia
10.3.9 Singapore
10.3.10 Vietnam
10.3.11 Rest of Asia Pacific
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Colombia
10.4.4 Chile
10.4.5 Peru
10.4.6 Rest of South America
10.5 Rest of the World (RoW)
10.5.1 Middle East
10.5.1.1 Saudi Arabia
10.5.1.2 United Arab Emirates
10.5.1.3 Qatar
10.5.1.4 Israel
10.5.1.5 Rest of Middle East
10.5.2 Africa
10.5.2.1 South Africa
10.5.2.2 Egypt
10.5.2.3 Morocco
10.5.2.4 Rest of Africa
11 STRATEGIC MARKET INTELLIGENCE
11.1 Industry Value Network and Supply Chain Assessment
11.2 White-Space and Opportunity Mapping
11.3 Product Evolution and Market Life Cycle Analysis
11.4 Channel, Distributor, and Go-to-Market Assessment
12 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
12.1 Mergers and Acquisitions
12.2 Partnerships, Alliances, and Joint Ventures
12.3 New Product Launches and Certifications
12.4 Capacity Expansion and Investments
12.5 Other Strategic Initiatives
13 COMPANY PROFILES
13.1 Insilico Medicine
13.2 Exscientia plc
13.3 BenevolentAI
13.4 Recursion Pharmaceuticals, Inc.
13.5 Schr?dinger, Inc.
13.6 Atomwise, Inc.
13.7 XtalPi Inc.
13.8 Generate Biomedicines
13.9 Deep Genomics Inc.
13.10 Relay Therapeutics, Inc.
13.11 IBM Corporation
13.12 Alphabet Inc.
13.13 Microsoft Corporation
13.14 NVIDIA Corporation
13.15 Absci Corporation
LIST OF TABLES
Table 1 Global Generative AI Molecule Discovery & Repurposing Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Generative AI Molecule Discovery & Repurposing Market, By Product (2023–2034) ($MN)
Table 3 Global Generative AI Molecule Discovery & Repurposing Market, By AI-Driven Drug Design Platforms (2023–2034) ($MN)
Table 4 Global Generative AI Molecule Discovery & Repurposing Market, By Molecule Generation Software (2023–2034) ($MN)
Table 5 Global Generative AI Molecule Discovery & Repurposing Market, By Drug Repurposing Engines (2023–2034) ($MN)
Table 6 Global Generative AI Molecule Discovery & Repurposing Market, By Virtual Screening Platforms (2023–2034) ($MN)
Table 7 Global Generative AI Molecule Discovery & Repurposing Market, By Other Products (2023–2034) ($MN)
Table 8 Global Generative AI Molecule Discovery & Repurposing Market, By Component (2023–2034) ($MN)
Table 9 Global Generative AI Molecule Discovery & Repurposing Market, By Software Platforms (2023–2034) ($MN)
Table 10 Global Generative AI Molecule Discovery & Repurposing Market, By AI Algorithms & Models (2023–2034) ($MN)
Table 11 Global Generative AI Molecule Discovery & Repurposing Market, By Data Libraries (2023–2034) ($MN)
Table 12 Global Generative AI Molecule Discovery & Repurposing Market, By Cloud Infrastructure (2023–2034) ($MN)
Table 13 Global Generative AI Molecule Discovery & Repurposing Market, By Computational Chemistry Tools (2023–2034) ($MN)
Table 14 Global Generative AI Molecule Discovery & Repurposing Market, By Other Components (2023–2034) ($MN)
Table 15 Global Generative AI Molecule Discovery & Repurposing Market, By Technology (2023–2034) ($MN)
Table 16 Global Generative AI Molecule Discovery & Repurposing Market, By Deep Learning (2023–2034) ($MN)
Table 17 Global Generative AI Molecule Discovery & Repurposing Market, By Transformer Models (2023–2034) ($MN)
Table 18 Global Generative AI Molecule Discovery & Repurposing Market, By Graph Neural Networks (2023–2034) ($MN)
Table 19 Global Generative AI Molecule Discovery & Repurposing Market, By Reinforcement Learning (2023–2034) ($MN)
Table 20 Global Generative AI Molecule Discovery & Repurposing Market, By Other Technologies (2023–2034) ($MN)
Table 21 Global Generative AI Molecule Discovery & Repurposing Market, By Application (2023–2034) ($MN)
Table 22 Global Generative AI Molecule Discovery & Repurposing Market, By Oncology Drug Discovery (2023–2034) ($MN)
Table 23 Global Generative AI Molecule Discovery & Repurposing Market, By Rare Disease Drug Development (2023–2034) ($MN)
Table 24 Global Generative AI Molecule Discovery & Repurposing Market, By Infectious Disease Research (2023–2034) ($MN)
Table 25 Global Generative AI Molecule Discovery & Repurposing Market, By CNS Drug Discovery (2023–2034) ($MN)
Table 26 Global Generative AI Molecule Discovery & Repurposing Market, By Immunology & Inflammation (2023–2034) ($MN)
Table 27 Global Generative AI Molecule Discovery & Repurposing Market, By Other Applications (2023–2034) ($MN)
Table 28 Global Generative AI Molecule Discovery & Repurposing Market, By End User (2023–2034) ($MN)
Table 29 Global Generative AI Molecule Discovery & Repurposing Market, By Pharmaceutical Companies (2023–2034) ($MN)
Table 30 Global Generative AI Molecule Discovery & Repurposing Market, By Biotechnology Companies (2023–2034) ($MN)
Table 31 Global Generative AI Molecule Discovery & Repurposing Market, By CROs (2023–2034) ($MN)
Table 32 Global Generative AI Molecule Discovery & Repurposing Market, By Academic Research Institutes (2023–2034) ($MN)
Table 33 Global Generative AI Molecule Discovery & Repurposing Market, By Other End Users (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
Table 1 Global Generative AI Molecule Discovery & Repurposing Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Generative AI Molecule Discovery & Repurposing Market, By Product (2023–2034) ($MN)
Table 3 Global Generative AI Molecule Discovery & Repurposing Market, By AI-Driven Drug Design Platforms (2023–2034) ($MN)
Table 4 Global Generative AI Molecule Discovery & Repurposing Market, By Molecule Generation Software (2023–2034) ($MN)
Table 5 Global Generative AI Molecule Discovery & Repurposing Market, By Drug Repurposing Engines (2023–2034) ($MN)
Table 6 Global Generative AI Molecule Discovery & Repurposing Market, By Virtual Screening Platforms (2023–2034) ($MN)
Table 7 Global Generative AI Molecule Discovery & Repurposing Market, By Other Products (2023–2034) ($MN)
Table 8 Global Generative AI Molecule Discovery & Repurposing Market, By Component (2023–2034) ($MN)
Table 9 Global Generative AI Molecule Discovery & Repurposing Market, By Software Platforms (2023–2034) ($MN)
Table 10 Global Generative AI Molecule Discovery & Repurposing Market, By AI Algorithms & Models (2023–2034) ($MN)
Table 11 Global Generative AI Molecule Discovery & Repurposing Market, By Data Libraries (2023–2034) ($MN)
Table 12 Global Generative AI Molecule Discovery & Repurposing Market, By Cloud Infrastructure (2023–2034) ($MN)
Table 13 Global Generative AI Molecule Discovery & Repurposing Market, By Computational Chemistry Tools (2023–2034) ($MN)
Table 14 Global Generative AI Molecule Discovery & Repurposing Market, By Other Components (2023–2034) ($MN)
Table 15 Global Generative AI Molecule Discovery & Repurposing Market, By Technology (2023–2034) ($MN)
Table 16 Global Generative AI Molecule Discovery & Repurposing Market, By Deep Learning (2023–2034) ($MN)
Table 17 Global Generative AI Molecule Discovery & Repurposing Market, By Transformer Models (2023–2034) ($MN)
Table 18 Global Generative AI Molecule Discovery & Repurposing Market, By Graph Neural Networks (2023–2034) ($MN)
Table 19 Global Generative AI Molecule Discovery & Repurposing Market, By Reinforcement Learning (2023–2034) ($MN)
Table 20 Global Generative AI Molecule Discovery & Repurposing Market, By Other Technologies (2023–2034) ($MN)
Table 21 Global Generative AI Molecule Discovery & Repurposing Market, By Application (2023–2034) ($MN)
Table 22 Global Generative AI Molecule Discovery & Repurposing Market, By Oncology Drug Discovery (2023–2034) ($MN)
Table 23 Global Generative AI Molecule Discovery & Repurposing Market, By Rare Disease Drug Development (2023–2034) ($MN)
Table 24 Global Generative AI Molecule Discovery & Repurposing Market, By Infectious Disease Research (2023–2034) ($MN)
Table 25 Global Generative AI Molecule Discovery & Repurposing Market, By CNS Drug Discovery (2023–2034) ($MN)
Table 26 Global Generative AI Molecule Discovery & Repurposing Market, By Immunology & Inflammation (2023–2034) ($MN)
Table 27 Global Generative AI Molecule Discovery & Repurposing Market, By Other Applications (2023–2034) ($MN)
Table 28 Global Generative AI Molecule Discovery & Repurposing Market, By End User (2023–2034) ($MN)
Table 29 Global Generative AI Molecule Discovery & Repurposing Market, By Pharmaceutical Companies (2023–2034) ($MN)
Table 30 Global Generative AI Molecule Discovery & Repurposing Market, By Biotechnology Companies (2023–2034) ($MN)
Table 31 Global Generative AI Molecule Discovery & Repurposing Market, By CROs (2023–2034) ($MN)
Table 32 Global Generative AI Molecule Discovery & Repurposing Market, By Academic Research Institutes (2023–2034) ($MN)
Table 33 Global Generative AI Molecule Discovery & Repurposing Market, By Other End Users (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
